Betta Pharmaceuticals

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.

Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs.

Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.

Hangzhou DAC Biotech Co., Ltd., established in 2012 and located in Hangzhou, China, specializes in the development of innovative cancer treatment drugs. The company focuses on creating monoclonal antibodies and small molecular cytotoxic drugs, particularly through the development of conjugates that combine these two types of therapies using smart linkers. These advanced drug formulations are designed to target malignant cells specifically, thereby minimizing damage to normal tissues. By reducing the toxicities associated with traditional chemical therapies, DAC Biotech aims to provide personalized and humanized treatment options for cancer patients.

Xcovery LLC is a biopharmaceutical company based in West Palm Beach, Florida, founded in 2006. The company specializes in developing targeted oncology therapies aimed at treating advanced tumors. Notably, Xcovery has developed X-396, a small molecule that inhibits anaplastic lymphoma kinase, alongside other kinase inhibitors targeting MET and PI3K/mTOR pathways. The company's focus is on creating low toxicity molecular targeted oral drugs that facilitate continuous therapy without the need for treatment interruptions. This approach aims to enhance the therapeutic window and improve treatment efficacy for various cancers, particularly in combination therapies where traditional treatments may be too toxic. The leadership team includes experienced professionals such as CEO Sheridan Snyder, who has a successful track record in biotechnology, and Chief Scientific Officer Dr. Chris Liang, known for his work on approved cancer therapies. Xcovery's mission is to advance next-generation treatments that improve the quality of life for cancer patients while addressing the challenges of treatment resistance.